Clinical Trial Update: A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammatory myopath…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antisynthetase Syndrome
• Dermatomyositis
• Idiopathic Inflammatory Myopathy
• Immune-mediated Necrotizing Myopathy
• Polymyositis

Drugs mentioned

• VYVGART (EFGARTIGIMOD ALFA)

Snippet

Sponsor: argenx | Conditions: Myositis, Active Idiopathic Inflammatory Myopathy | Phase 3 | Status: ENROLLING_BY_INVITATION